#Israel #financial results #medical technology #Yokneam #InMode Ltd

InMode Reports Financial Results for Q2 2026

InMode Ltd. (NASDAQ: INMD), a prominent player in innovative medical technologies, has released its consolidated financial data for the second quarter of 2026. For the quarter ending June 30, the company reported revenues totaling $95.6 million, reflecting a stable performance that mirrors the figures from the same period in 2025. This consistency showcases InMode's resilience in the competitive medical technology sector.

Key Financial Highlights

The financial highlights for Q2 2026 are as follows:

• - Total Revenues: $95.6 million
• - Revenue from Consumables and Services: $22.3 million, which shows a 13% increase compared to Q2 2025.
• - GAAP Operating Income: $12.3 million; Non-GAAP Operating Income: $16.0 million.
• - Cash Position: $501.1 million as of June 30, 2026.
• - Share Buyback: InMode completed the repurchase of 6.38 million ordinary shares for an aggregate purchase price of $87.8 million under its previously announced buyback program.

U.S. GAAP Results

For the second quarter of 2026, the company reported:

• - Net Income: $17.1 million; earnings of $0.29 per diluted share, compared to $26.7 million or $0.42 per diluted share the previous year.
• - Gross Margin: 75%, down from 80% year-over-year.

The decrease in profitability metrics is attributed to heightened costs of goods sold, shifts in product mix, and increased marketing expenditures to maintain market share.

Management Insights

Moshik Itzkovich, Chief Financial Officer of InMode, remarked on the company’s performance: “Revenue has remained stable compared to the previous year, demonstrating the ongoing demand for our U.S. capital equipment. Stability in revenue generation is expected to persist throughout the year as we continue investing in growth opportunities.”

Market Performance

InMode's performance in Asian markets contributed positively, recording a significant rise in quarterly revenues for consumables and services, which was primarily driven by international sales. The company continues to cultivate its presence globally, focusing on enhancing its product lines across various medical fields, including plastic surgery and dermatology.

Financial Outlook for 2026

Looking ahead, InMode management has provided guidance for the full fiscal year ending December 31, 2026, projecting revenues between $365 million and $375 million. The company expects a non-GAAP gross margin between 74% and 76%, with projected earnings per diluted share ranging from $1.29 to $1.34. However, this outlook remains subject to change based on market conditions and internal performance metrics.

Upcoming Strategic Initiatives

Despite ongoing regional conflicts impacting operational contexts, InMode has reported no significant adverse effects on its operations to date. The company is closely monitoring the political landscape to ensure its strategies remain aligned with market conditions and consumer needs.

Conclusion

InMode's steadfast revenue in Q2 2026, complemented by strategic investments and a robust cash position, positions it well for future growth. The leadership is optimistic about navigating the challenges ahead while expanding its global footprint in the medical technology arena. For more updates, visit InMode's official website.